DURECT (DRRX) Competitors $0.57 +0.02 (+4.02%) As of 06/10/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. XCUR, MGX, IRD, ANL, PDSB, CTOR, ASRT, TELO, VHAQ, and IKNAShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Exicure (XCUR), Metagenomi (MGX), Opus Genetics (IRD), Adlai Nortye (ANL), PDS Biotechnology (PDSB), Citius Oncology (CTOR), Assertio (ASRT), Telomir Pharmaceuticals (TELO), Viveon Health Acquisition (VHAQ), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Exicure Metagenomi Opus Genetics Adlai Nortye PDS Biotechnology Citius Oncology Assertio Telomir Pharmaceuticals Viveon Health Acquisition Ikena Oncology Exicure (NASDAQ:XCUR) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Which has better earnings and valuation, XCUR or DRRX? Exicure has higher earnings, but lower revenue than DURECT. DURECT is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K124.96-$16.91M-$4.81-2.06DURECT$1.86M9.62-$27.62M-$0.15-3.83 Does the media prefer XCUR or DRRX? In the previous week, Exicure and Exicure both had 1 articles in the media. Exicure's average media sentiment score of 1.89 equaled DURECT'saverage media sentiment score. Company Overall Sentiment Exicure Very Positive DURECT Very Positive Which has more volatility and risk, XCUR or DRRX? Exicure has a beta of 3.71, suggesting that its stock price is 271% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Do analysts rate XCUR or DRRX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor XCUR or DRRX? DURECT received 307 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 60.89% of users gave DURECT an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformExicureOutperform Votes947.37% Underperform Votes1052.63% DURECTOutperform Votes31660.89% Underperform Votes20339.11% Do insiders & institutionals have more ownership in XCUR or DRRX? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 3.9% of Exicure shares are owned by insiders. Comparatively, 3.2% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is XCUR or DRRX more profitable? Exicure has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Exicure's return on equity of -190.90% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -190.90% -36.75% DURECT -198.58%-300.62%-65.17% SummaryExicure beats DURECT on 8 of the 14 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.85M$6.78B$5.55B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-0.948.7927.2220.17Price / Sales9.62263.83423.71161.98Price / CashN/A65.8538.2534.64Price / Book1.156.677.134.72Net Income-$27.62M$143.49M$3.23B$247.80M7 Day Performance-0.52%5.15%3.78%2.75%1 Month Performance-21.34%15.42%13.34%9.70%1 Year Performance-60.34%6.02%32.21%14.51% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT0.9151 of 5 stars$0.58+4.0%N/A-59.2%$17.85M$1.86M-0.9480Positive NewsXCURExicure1.3043 of 5 stars$10.46+6.0%N/A+2,796.6%$66.09M$500,000.00-5.0550Positive NewsUpcoming EarningsMGXMetagenomi2.2386 of 5 stars$1.76+3.5%$13.00+638.6%-75.6%$65.79M$45.26M-0.83236IRDOpus Genetics2.1059 of 5 stars$1.09+9.6%$7.33+572.8%N/A$65.03M$13.65M-1.0014Positive NewsGap UpHigh Trading VolumeANLAdlai Nortye1.2666 of 5 stars$1.76-3.3%$9.00+411.4%-57.2%$64.94M$5M0.00127Gap DownHigh Trading VolumePDSBPDS Biotechnology1.9818 of 5 stars$1.41+2.2%$9.00+538.3%-40.4%$64.45MN/A-1.2220News CoverageAnalyst ForecastGap UpCTORCitius OncologyN/A$0.89-1.1%$3.00+237.0%N/A$63.69MN/A0.00N/AGap DownASRTAssertio2.0703 of 5 stars$0.66-1.2%$2.75+318.8%-39.9%$63.63M$119.00M-0.9020Positive NewsTELOTelomir Pharmaceuticals2.3188 of 5 stars$2.10+8.0%$15.00+614.3%-62.0%$62.50MN/A-3.621Gap UpVHAQViveon Health AcquisitionN/A$11.00flatN/A+10.0%$62.26MN/A0.002High Trading VolumeIKNAIkena Oncology3.6531 of 5 stars$1.28+7.6%$3.00+134.4%-18.1%$61.77M$659,000.00-1.0470 Related Companies and Tools Related Companies XCUR Competitors MGX Competitors IRD Competitors ANL Competitors PDSB Competitors CTOR Competitors ASRT Competitors TELO Competitors VHAQ Competitors IKNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
